Skip to main content
Perspective
Assessing potential cures: are there distinctive elements of value beyond health gain?
- Saskia Hendriks and
- Steven D Pearson
pp255–265
Published Online:5 March 2021
Meta-Analysis
Comparative efficacy of dabrafenib + trametinib versus treatment options for metastatic melanoma in first-line settings
- Jing Wu,
- Jaydeep Das,
- Manik Kalra, and
- Barbara Ratto
pp267–280
Published Online:15 January 2021
Short Communication
Estimates of the value of life lost from COVID-19 in Ohio
- Peter J Mallow
pp281–284
Published Online:17 February 2021
Research Article
Do implantable loop recorders impact the survival of patients with recurrent unexplained syncope?
- Christian Perings,
- Claudia Wolff,
- Adrian Wilk,
- Andreas Witthohn,
- Rainer Voss, and
- Karin Rybak
pp285–294
Published Online:27 January 2021
Endovascular treatment with the Enterprise stent versus the Neuroform or Low-Profile Visualized Intraluminal Support stent for unruptured aneurysms
- Reade De Leacy,
- Emilie Kottenmeier,
- Stephanie HY Lee,
- Rahul Khanna, and
- Alejandro M Spiotta
pp295–305
Published Online:17 February 2021
Impact of an oral anticoagulation self-monitoring and self-management program in patients with mechanical heart valve prosthesis
- Pedro Blanch,
- Román Freixa-Pamias,
- Marta Gambau,
- Raul Lafuente, and
- Luca Basile
pp307–314
Published Online:17 February 2021
End-of-life cost for lung cancer patients in Greece: a hospital-based retrospective study
- Eleni Kokkotou,
- Garyfallia Stefanou,
- Nikolaos Syrigos,
- George Gourzoulidis,
- Eleutheria Ntalakou,
- Anna Apostolopoulou,
- Andriani Charpidou, and
- Georgia Kourlaba
pp315–324
Published Online:19 February 2021
Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost–effectiveness analysis
- Javier Aguilar-Serra,
- Vicente Gimeno-Ballester,
- Alfonso Pastor-Clerigues,
- Javier Milara,
- Ezequiel Marti-Bonmati,
- Cristina Trigo-Vicente, and
- Julio Cortijo
pp325–335
Published Online:26 February 2021
Corrigendum
Corrigendum
pp337–337
Published Online:8 January 2021
- Correction(s) for this article
US cost–effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma
- Volume 9Issue 14Journal of Comparative Effectiveness Research
- 8 October 2020